# Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)

> **NCT01212913** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 161 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** INSULIN GLARGINE
- **DRUG:** INSULIN GLULISINE
- **DRUG:** Insulin aspart

## Key facts

- **NCT ID:** NCT01212913
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2013-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01212913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01212913, "Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01212913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*